Related Experiment Video
Updated: Dec 10, 2025
09:06
Whole-brain Segmentation and Change-point Analysis of Anatomical Brain MRI—Application in Premanifest Huntington's Disease
Published on: June 9, 2018
12.5K
Does pallidal neuromodulation influence cognitive decline in Huntington's disease?
Emily Sanrey1,2, Valérie Macioce3, Victoria Gonzalez4,5
1Unité Pathologies Cérébrales Résistantes, Département de Neurochirurgie, Institut génomique Fonctionnelle, Hôpital Gui de Chauliac, INSERM, CNRS, Univ Montpellier, CHU Montpellier, 80 Avenue Augustin Fliche, 34 295, Montpellier Cedex 5, France. e-sanrey@chu-montpellier.fr.
Journal of Neurology
|September 5, 2020
Summary
Continuous Electrical Neuromodulation (CEN) of the globus pallidus internus (GPi) stabilized cognitive decline in Huntington
Area of Science:
- Neurology
- Neuroscience
- Neurosurgery
Background:
- Huntington's disease (HD) is a progressive neurodegenerative disorder.
- HD causes motor, psychiatric, and cognitive decline.
- Globus pallidus internus (GPi) neuromodulation is used for chorea in HD.
Purpose of the Study:
- To assess the long-term impact of GPi continuous electrical neuromodulation (CEN) on cognitive function in HD patients.
- To evaluate the progression of cognitive decline in HD patients undergoing GPi-CEN.
Main Methods:
- A cohort of 13 Huntington's disease patients underwent GPi neuromodulation.
- Patients were assessed pre- and post-operatively over a 5-year follow-up.
- The Mattis Dementia Rating Scale (MDRS) measured global cognitive function.
Main Results:
- Chorea improved by 56% postoperatively in all patients.
- Global cognitive function remained stable for the first 3 years of GPi-CEN treatment.
- Cognitive decline was delayed despite ongoing disease progression.
Conclusions:
- GPi-CEN shows a positive influence on cognitive function in HD patients.
- This neuromodulation technique may delay cognitive decline in early-stage HD.
- GPi-CEN offers benefits beyond chorea reduction in Huntington's disease.
Related Concept Videos
01:24Parkinson's Disease: Treatment
811
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
811
01:22Alzheimer's Disease: Treatment
635
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
635
01:15Parkinson's Disease: Overview
1.5K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.5K
01:26Alzheimer's Disease: Overview
1.4K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.4K
01:37Neural Regulation
42.6K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
42.6K